Shaily Engineering Plastics (501423) Q2 25/26 earnings summary

Executive summary

• Q2 FY26 revenue grew 34% year-over-year to INR 257 crores, driven by a 163% surge in healthcare segment sales and strong margin expansion.

• EBITDA margin expanded by over 1,000 basis points to 31.8%, with PAT up 134% year-over-year to INR 51 crores.

• Company launched the next-gen GLP-1 device, Axiom Max, and signed four new projects across GLP-1 and other therapies.

• Installed 19 new machines as part of capacity expansion and secured new business in home furnishing and automotive segments.

• Unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, were reviewed and approved by the Board.

Financial highlights

• Consolidated revenue reached ₹256.7 Cr in Q2 FY26 and ₹503.3 Cr in H1 FY26, up 34% and 36% year-over-year, respectively.

• Q2 EBITDA: INR 82 crores vs INR 41 crores (100% growth); EBITDA margin at 31.8%.

• Q2 PAT: INR 51 crores vs INR 22 crores (134% growth); PAT margin at 20%.

• Basic EPS (consolidated) for Q2 FY26 was ₹11.15, up from ₹4.78 in Q2 FY25.

• Cash PAT increased by 97% in Q2 FY26 and 94% in H1 FY26.

Outlook and guidance

• Healthcare segment expected to grow 30%-40% annually for the next few years.

• Commercial supplies for consumer electronics to begin in H2 FY26, but not expected to be significant next year.

• Expansion of manufacturing capacity and new project wins position the company for sustained performance.

• No formal guidance on total pen or GLP-1 pen volumes; majority of Canadian filings use company devices.